Table 2 Short-term efficacy of 9 evaluable patients with exploratory multi-line therapy
Short-term efficacy | Monotherapy, n (%) | Combined Treatment, n (%) |
|---|---|---|
Complete response (CR) | 0 (0) | 0 (0) |
Partial response (PR) | 2 (33.3) | 0 (0) |
Stable disease (SD) | 1 (16.7) | 1 (33.3) |
Progression disease (PD) | 3 (50.0) | 2 (66.7) |
Objective response rate (ORR) | 2/6 (33.3) | 0 (0) |
Disease control rate (DCR) | 3/6 (50.0) | 1/3 (33.3) |